Association of preservative-free propofol use and outcome in critically ill patients

American Journal of Infection Control

Volumn 39, Issue 2, 2011, Pages 141-147

  Haddad, Samir ^a   Tamim, Hani ^b   Memish, Ziad A ^c   Arabi, Yaseen ^a,b  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^c MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

Infection; intensive care unit; mortality; sepsis

Indexed keywords

GLUCOSE; INSULIN; PROPOFOL;

ADULT; AGED; APACHE; ARTICLE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; COHORT ANALYSIS; CONTINUOUS INFUSION; DISEASE SEVERITY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SEPTIC SHOCK; TERMINALLY ILL PATIENT; TRACHEOBRONCHITIS; UROSEPSIS;

COHORT STUDIES; CRITICAL ILLNESS; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HOSPITAL MORTALITY; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE UNITS; MALE; PRESERVATIVES, PHARMACEUTICAL; PROPOFOL;

EID: 79952314260     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2010.05.027     Document Type: Article

References (56)

1. Marik PE. Propofol: therapeutic indications and side effects. Curr Pharm Des 2004;10:3639-49. (Pubitemid 39386579)
2. AstraZeneca. Core data sheet: DIPRIVAN 10mg/mL (1%) and 20 mg/mL (2%) emulsion for injection or infusion. Available from: http://www.anaesthesia-az. com/sites/156/imagebank/typearticleparam509637/CDS1Diprivan.pdf. Accessed March 5, 2008.
3. Tsao CM, Ho ST, Liaw WJ, Chen A,Wu CC. Combined effects of propofol and dexamethasone on rats with endotoxemia. Crit Care Med 2008;36:887-94.
4. Jawan B, Kao YH, Goto S, Pan MC, Lin YC, Hsu LW, et al. Propofol pretreatment attenuates LPS-induced granulocyte-macrophage colony-stimulating factor production in cultured hepatocytes by suppressing MAPK/ERK activity and NF-kappaB translocation. Toxicol Appl Pharmacol 2008;229:362-73.
5. Chen HI, Hsieh NK, Kao SJ, Su CF. Protective effects of propofol on acute lung injury induced by oleic acid in conscious rats. Crit Care Med 2008;36:1214-21. (Pubitemid 351482671)
6. Shao H, Li J, Zhou Y, Ge Z, Fan J, Shao Z, et al. Dose-dependent protective effect of propofol against mitochondrial dysfunction in ischaemic/reperfused rat heart: role of cardiolipin. Br J Pharmacol 2008;153:1641-9. (Pubitemid 351536002)
7. Inal MT, Memis D, Vatan I, Cakir U, Yildiz B. Late-onset pulmonary edema due to propofol. Acta Anaesthesiol Scand 2008;52:1015-7. (Pubitemid 351951773)
8. Ypsilantis P, Politou M, Mikroulis D, Pitiakoudis M, Lambropoulou M, Tsigalou C, et al. Organ toxicity and mortality in propofol-sedated rabbits under prolonged mechanical ventilation. Anesth Analgesia 2007;105:155-66. (Pubitemid 46975862)
9. Trampitsch E, Oher M, Pointner I, Likar R, Jost R, Schalk HV. Propofol infusion syndrome. Anaesthesist 2006;55:1166-8. (Pubitemid 44900084)
10. Sabsovich I, Rehman Z, Yunen J, Coritsidis G. Propofol infusion syndrome: a case of increasing morbidity with traumatic brain injury. Am J Crit Care 2007;16:82-5.
11. Zaccheo M, Bucher D. Propofol infusion syndrome: a rare complication with potentially fatal results. Crit Care Nurse 2008;28:18-25.
12. Vaslie B, Rasulo F, Candiani A, Latronico N. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003;29:1417-25. (Pubitemid 37153585)
13. Kang TM. Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002;30:119-41.
14. Ernest D, French C. Propofol infusion syndrome: report of an adult fatality. Anaesth Intensive Care 2003;36:1453-66.
15. Casserly B, O'Mahony E, Timm EG, Haqqie S, Eisele G, Urizar R. Propofol infusion syndrome: an unusual cause of renal failure. Am J Kidney Dis 2004;44:98-101.
16. Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet 2001;357:117-8. (Pubitemid 32094917)
17. Bennett S, McNeil M, Bland L, Arduino M, Villarino M, Perrotta D, et al. postoperative infections traced to contamination of an intravenous anesthetic, propofol. N Engl J Med 1995;333:147-54.
18. Daily MJ, Dickey JB, Packo KH. Endogenous Candida endophthalmitis after intravenous anesthesia with propofol. Arch Ophthalmol 1991;109:1081-4.
19. McHugh GJ, Roper GM. Propofol emulsion and bacterial contamination. Can J Anaesth 1995;42:801-4.
20. Bach A, Motsch J, Schmidt H, Böttiger BW, Böhrer H, Martin E, et al. In-use contamination of propofol: a clinical study. Eur J Anaesthesiol 1997;14:178-83. (Pubitemid 27427443)
21. Kuehnert MJ, Webb RM, Jochimsen EM, Hancock GA, Arduino MJ, Hand S, et al. Staphylococcus aureus bloodstream infections among patients undergoing electroconvulsive therapy traced to breaks in infection control and possible extrinsic contamination by propofol. Anesth Analgesia 1997;85:420-5. (Pubitemid 27349157)
22. McNeil MM, Lasker BA, Lott TJ, Jarvis WR. Postsurgical Candida albicans infections associated with an extrinsically contaminated intravenous anesthetic agent. J Clin Microbiol 1999;37:1398-403. (Pubitemid 29187807)
23. Henry B, Plante-Jenkins C, Ostrowska K. An outbreak of Serratia marcescens associated with the anesthetic agent propofol. Am J Infect Control 2001;29:312-5. (Pubitemid 32958568)
24. Sklar GE. Propofol and postoperative infections. Ann Pharmacother 1997;31:1521-3. (Pubitemid 28013184)
25. Webb SA, Roberts B, Breheny FX, Golledge CL, Cameron PD, van Heerden PV. Contamination of propofol infusion in an intensive care unit: incidence and clinical significance. Anaesth Intensive Care 1998;26:162-4. (Pubitemid 28172038)
26. Arabi Y, Alshimemeri A, Taher S. Weekend and weeknight admissions have the same outcome of weekday admissions to an intensive care unit with onsite intensivist coverage. Crit Care Med 2006;34:605-11.
27. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41. (Pubitemid 34112188)
28. Kress J, Pohlman A, O'Connor M, Hall J. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000;342:1471-7. (Pubitemid 30318270)
29. Arabi Y, Haddad S, Hawes R, Moore T, Pillay M, Naidu B, et al. Changing sedation practices in the intensive care unit. Middle East J Anesthesiol 2007;19:429-47.
30. Haddad S, Arabi Y, Al-Dawood A, Al-Qahtani S, Pillay M, Naidu B, et al. Sedation in the ICU: Are we achieving goals? Middle East J Anesthesiol 2009;20:389-96.
31. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health care-associated pneumonia 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53(RR-3):1-36.
32. O'Grady N, Alexander M, Dellinger E, Gerberding J, Heard S, Maki D, et al. CDC guidelines for the prevention of intravascular catheter- related infections. MMWR Recomm Rep 2002;51(RR-10):1-26.
33. Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri AA, Memish ZA, Haddad SH, et al. Intensive versus conventional insulin therapy: a randomized control trial in medical and surgical critically ill patients. Crit Care Med 2008;36:3190-7.
34. Current Controlled Trials Registry. ISRCTN07413772. Available from: http://www.controlled-trials.com/ISRCTN07413772/07413772. Accessed March 25, 2010.
35. Pearson ML. Guidelines for prevention of intravascular device-related infections, part I, intravascular device-related infections: an overview. Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996;24:262-77.
36. American Society of Anesthesiologists, Committee on Occupational Health of Operating Room Personnel. Recommendations for infection control for the practice of anesthesiology. 2nd ed. Park Ridge (IL): American Society of Anesthesiologists; 1998.
37. Berry AJ. Recommendations for handling parenteral medications used for anesthesia or sedation. Pittsburgh (PA): Anesthesia Patient Safety Foundation; 1995.
38. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
39. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6. (Pubitemid 36444440)
40. Emori TG, Culver DH, HoranTC, JarvisWR,WhiteJW, Olson DR, et al. National nosocomial infections surveillance system (NNIS): description of surveillance methods. Am J Infect Control 1991;19:19-35.
41. Heldmann E, Brown DC, Shofer F. The association of propofol usage with postoperative wound infection rate in clean wounds: a retrospective study. Vet Surg 1999;28:256-9. (Pubitemid 129742506)
42. Postsurgical infections associated with an extrinsically contaminated intravenous anesthetic agent-California, Illinois, Maine, and Michigan, 1990. MMWR Morb Mortal Wkly Rep 1990;39:426-7, 433.
43. Vanlersberghe C, Camu F. Propofol. Handb Exp Pharmacol 2008;182:227-52.
44. O'Donnell NG, McSharry CP, Wilkinson PC, Asbury AJ. Comparison of the inhibitory effect of propofol, thiopentone and midazolam on neutrophil polarization in vitro in the presence or absence of human serum albumin. Br J Anaesth 1992;69:70-4.
45. Kelbel I, Koch T,Weber A, Schiefer HG, Van Ackern K, Neuhof H. Alterations of bacterial clearance induced by propofol. Acta Anaesthesiol Scand 1999;43:71-6. (Pubitemid 29014115)
46. Sanchez-Izquierdo-Riera JA, Caballero-Cubedo RE, Perez-Vela JL, Ambros-Checa A, Cantalapledra-Santiago JA, Alted-Lopez E. Propofol versus midazolam: safety and efficacy for sedating the severe trauma patient. Anesth Analg 1998;86:1219-24. (Pubitemid 28249240)
47. El-Ebiary M, Torres A, Ramirez J, Xaubet A, Rodriguez-Roisin R. Lipid deposition during the long-term infusion of propofol. Crit Care Med 1995;23:1928-30.
48. Short M, Kennedy K, Villaran Y. Omega-6 fatty acid exposure from propofol infusions (abstract). Chest 2009;136:42S.
49. Krishnan JA, Parce PB, Martinez A, Diette GB, Brower RG. Caloric intake in medical ICU patients: consistency of care with guidelines and relationship to clinical outcomes. Chest 2003;124:297-305. (Pubitemid 36851366)
50. Noriega RL, Angulo GB, Alalorre MAM, Molina LR, Torres NPC. Extrinsic bacterial contamination of propofol. Rev Mex Anest 1999;22:59-67 (in Spanish).
51. Fukada T, Ozaki M. Bacterial growth in two propofol formulations recently used in Japan. Life Supp Anesth 2004;11:1174-5.
52. Fukada T, Ozaki M. Microbial growth in propofol formulations with disodium edetate and the influence of venous access system dead space. Anaesthesia 2007;6:575-80. (Pubitemid 46796318)
53. Ovechkin AM, Gagarina IV. Diprivan-EDTA: choice in favor of patient safety. Anesteziol Reanimatol 2002;3:52-6.
54. Jansson JR, Fukada T, Ozaki M. Propofol EDTA and reduced incidence of infection. Anaesth Intensive Care 2006;34:362-8.
55. Güzelant A, Apiliogullari S, Kara I. The preventive effect of diphenhydramine on bacterial growth in propofol: a laboratory study. Eur J Anaesthesiol 2008;25:737-40.
56. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6. (Pubitemid 20255621)